These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20981257)

  • 1. The add-on effect of solifenacin for patients with remaining overactive bladder after treatment with tamsulosin for lower urinary tract symptoms suggestive of benign prostatic obstruction.
    Masumori N; Tsukamoto T; Yanase M; Horita H; Aoki M
    Adv Urol; 2010; 2010():205251. PubMed ID: 20981257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of combination therapy of tamsulosin and solifenacin for mild and moderate benign prostatic hyperplasia with overactive bladder].
    Gao ZW; Xin SY; Zhang JG; Ren XQ; Shang YF; Zhang W; Li HB; Xiao F; Shao CS
    Zhonghua Nan Ke Xue; 2014 Mar; 20(3):239-43. PubMed ID: 24738461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
    Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ
    Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Who Would Benefit from Solifenacin Add-On Therapy to Tamsulosin for Overactive Bladder Symptoms Associated with Benign Prostatic Hyperplasia?
    Obata J; Matsumoto K; Yamanaka H; Ninomiya A; Nakamura S
    Low Urin Tract Symptoms; 2013 Sep; 5(3):145-9. PubMed ID: 26663450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Add-on treatment with mirabegron may improve quality of life in patients with benign prostatic hyperplasia complaining of persistent storage symptoms after tamsulosin monotherapy.
    Kang TW; Chung HC
    Ther Adv Urol; 2020; 12():1756287220974130. PubMed ID: 33414845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemic investigation of benign prostatic obstruction with coexisting overactive bladder in Shanghai Pudong New Area and its impact on the health-related quality of life.
    Yi QT; Gong M; Chen CH; Hu W; Zhu RJ
    BMC Urol; 2019 Sep; 19(1):82. PubMed ID: 31481034
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence with solifenacin add-on therapy in men with benign prostate obstruction and residual symptoms of overactive bladder after tamsulosin monotherapy.
    Lee YS; Lee KS; Kim JC; Hong S; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK
    Int J Clin Pract; 2014 Dec; 68(12):1496-502. PubMed ID: 25284747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-release tolterodine with or without tamsulosin in men with lower urinary tract symptoms and overactive bladder: effects on urinary symptoms assessed by the International Prostate Symptom Score.
    Kaplan SA; Roehrborn CG; Chancellor M; Carlsson M; Bavendam T; Guan Z
    BJU Int; 2008 Nov; 102(9):1133-9. PubMed ID: 18510659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initial Use of High-Dose Anticholinergics Combined with Alpha-Blockers for Male Lower Urinary Tract Symptoms with Overactive Bladder: A Prospective, Randomized Preliminary Study.
    Lee KW; Hur KJ; Kim SH; Cho SY; Bae SR; Park BH; Lee YS; Han CH; Kim HW
    Low Urin Tract Symptoms; 2017 Sep; 9(3):129-133. PubMed ID: 27028190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of solifenacin plus tamsulosin OCAS in men with voiding and storage lower urinary tract symptoms: results from a phase 2, dose-finding study (SATURN).
    Van Kerrebroeck P; Haab F; Angulo JC; Vik V; Katona F; Garcia-Hernandez A; Klaver M; Traudtner K; Oelke M
    Eur Urol; 2013 Sep; 64(3):398-407. PubMed ID: 23537687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of improvement in lower urinary tract symptoms on sexual function in men: tamsulosin monotherapy vs. combination therapy of tamsulosin and solifenacin.
    Ko K; Yang DY; Lee WK; Kim SW; Moon du G; Moon KH; Park NC; Park JK; Son HC; Lee SW; Hyun JS; Park K
    Korean J Urol; 2014 Sep; 55(9):608-14. PubMed ID: 25237463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of Tamsulosin Combined With Solifenacin on Lower Urinary Tract Symptoms: Evidence From a Systematic Review, Meta-Analysis, and Trial Sequential Analysis of Randomized Controlled Trials.
    Song Y; Chen G; Huang P; Hu C; Liu X
    Front Pharmacol; 2020; 11():763. PubMed ID: 32528291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of mirabegron versus solifenacin as additional therapy for persistent OAB symptoms after tamsulosin monotherapy in men with probable BPO.
    Soliman MG; El-Abd SA; Tawfik AM; Radwan MH; El-Abd AS
    World J Urol; 2021 Jun; 39(6):2049-2054. PubMed ID: 32869151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of initial combined tamsulosin and solifenacin therapy for overactive bladder and bladder outlet obstruction secondary to benign prostatic hyperplasia: a prospective, randomized, multicenter study.
    Lee SH; Byun SS; Lee SJ; Kim KH; Lee JY
    Int Urol Nephrol; 2014 Mar; 46(3):523-9. PubMed ID: 24097273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of lower urinary tract symptoms/benign prostatic hyperplasia treatment with tamsulosin and solifenacin combination therapy on erectile function.
    Seo DH; Kam SC; Hyun JS
    Korean J Urol; 2011 Jan; 52(1):49-54. PubMed ID: 21344031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study).
    Yamanishi T; Asakura H; Seki N; Tokunaga S
    Low Urin Tract Symptoms; 2019 May; 11(3):115-121. PubMed ID: 30358116
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy of single-tablet combinations of solifenacin and tamsulosin oral controlled absorption system in men with storage and voiding lower urinary tract symptoms: results from the NEPTUNE Study and NEPTUNE II open-label extension.
    Drake MJ; Chapple C; Sokol R; Oelke M; Traudtner K; Klaver M; Drogendijk T; Van Kerrebroeck P;
    Eur Urol; 2015 Feb; 67(2):262-70. PubMed ID: 25070148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Responder and health-related quality of life analyses in men with lower urinary tract symptoms treated with a fixed-dose combination of solifenacin and tamsulosin oral-controlled absorption system: results from the NEPTUNE study.
    Drake MJ; Sokol R; Coyne K; Hakimi Z; Nazir J; Dorey J; Klaver M; Traudtner K; Odeyemi IA; Oelke M; van Kerrebroeck P;
    BJU Int; 2016 Jan; 117(1):165-72. PubMed ID: 25907003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size.
    Roehrborn CG; Kaplan SA; Jones JS; Wang JT; Bavendam T; Guan Z
    Eur Urol; 2009 Feb; 55(2):472-9. PubMed ID: 18583022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.
    Roehrborn CG; Barkin J; Tubaro A; Emberton M; Wilson TH; Brotherton BJ; Castro R
    BJU Int; 2014 Apr; 113(4):623-35. PubMed ID: 24127818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.